Clinical Trial Update: A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer [Phase 1]

View source ↗

Summary

This phase 1 trial evaluated the combination of tamoxifen and fenretinide (4-HPR) in individuals at high risk for developing breast cancer; the study has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fenretinide (fenretinide)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Cancer, Breast Neoplasms | Phase 1 | Status: COMPLETED